Farallon Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-8,250,000
| Closed | -$31.4M | – | 132 |
|
|
2020
Q1 | $31.4M | Hold |
8,250,000
| – | – | 0.27% | 53 |
|
|
2019
Q4 | $42M | Buy |
8,250,000
+900,000
| +12% | +$4.58M | 0.28% | 58 |
|
|
2019
Q3 | $37.2M | Buy |
7,350,000
+1,806,614
| +33% | +$9.13M | 0.28% | 52 |
|
|
2019
Q2 | $34.2M | Buy |
5,543,386
+1,342,566
| +32% | +$8.28M | 0.22% | 62 |
|
|
2019
Q1 | $19.5M | Hold |
4,200,820
| – | – | 0.15% | 71 |
|
|
2018
Q4 | $17.6M | Buy |
4,200,820
+588,000
| +16% | +$2.47M | 0.13% | 68 |
|
|
2018
Q3 | $22.7M | Buy |
3,612,820
+961,720
| +36% | +$6.03M | 0.13% | 62 |
|
|
2018
Q2 | $21.3M | Buy |
+2,651,100
| New | +$21.3M | 0.13% | 62 |
|